Novel Approach for Predicting Occult Lymph Node Metastasis in Peripheral Clinical Stage I Lung Adenocarcinoma

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2019 Jun 11

PMID 31179083

Citations 15

Authors

Cheng-Yang Song

Daisuke Kimura

Takehiro Sakai

Takao Tsushima

Ikuo Fukuda

Affiliations

Soon will be listed here.

Abstract

Background: Occult nodal metastasis results in a poor prognosis for lung cancer patients. The aim of this study was to develop an efficient approach for predicting occult nodal metastasis in peripheral clinical stage I lung adenocarcinoma.

Methods: Data for 237 peripheral clinical stage I lung adenocarcinoma patients who underwent complete resection were retrospectively reviewed. Univariate and multivariate analyses were performed to investigate predictors of occult nodal metastasis. Kaplan-Meier analysis was performed for survival.

Results: Occult nodal metastasis was detected in 26/237 (11.0%) patients. Nodule type, tumor SUVmax, whole tumor size, solid tumor size, and preoperative serum carcinoembryonic antigen (CEA) were identified as preoperative predictors of occult nodal metastasis (all P<0.05). Solid tumor size (P<0.001) and preoperative serum CEA (P=0.004) were identified as independent predictors on multivariate analysis. A prediction model was established using the independent predictors. The occult nodal metastasis rate was 2.4% with solid tumor size ≤2.3 cm (low-risk group), 17.0% with solid tumor size >2.3 cm and CEA ≤5 ng/mL (moderate-risk group), and 56.0% with solid tumor size >2.3 cm and CEA >5 ng/mL (high-risk group). The occult nodal metastasis rate was significantly higher in papillary-predominant (11.0%) and solid-predominant subtypes (28.6%; P=0.001). Patients having a micropapillary component had a significantly higher occult nodal metastasis rate (24.2%) compared with no micropapillary component (P=0.007). Histological subtype with micropapillary component and all preoperative predictors were significant prognostic factors affecting disease-free survival (DFS) (all P<0.05).

Conclusions: A novel approach to predict occult nodal metastasis was developed for peripheral clinical stage I lung adenocarcinoma. It would be helpful for selecting candidates for stereotactic ablative radiotherapy (SABR) or wedge resection and mediastinoscopy or endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA). Complete nodal dissection should be performed for moderate to high-risk patients or patients with poor histologic subtypes.

Citing Articles

CT-based radiomics-deep learning model predicts occult lymph node metastasis in early-stage lung adenocarcinoma patients: A multicenter study.

Yin X, Lu Y, Cui Y, Zhou Z, Wen J, Huang Z Chin J Cancer Res. 2025; 37(1):12-27.

PMID: 40078558 PMC: 11893343. DOI: 10.21147/j.issn.1000-9604.2025.01.02.

Enhancing Thoracic Surgery with AI: A Review of Current Practices and Emerging Trends.

Aleem M, Khan J, Younes A, Sabbah B, Saleh W, Migliore M Curr Oncol. 2024; 31(10):6232-6244.

PMID: 39451768 PMC: 11506543. DOI: 10.3390/curroncol31100464.

CT-based radiomic consensus clustering association with tumor biological behavior in clinical stage IA adenocarcinoma: a retrospective study.

Wen X, Liu M, Qiu B, Wang Y, Jiang J, Zhang X Transl Lung Cancer Res. 2024; 13(8):1794-1806.

PMID: 39263010 PMC: 11384472. DOI: 10.21037/tlcr-24-283.

Dysfunction of CD8 T cells around tumor cells leads to occult lymph node metastasis in NSCLC patients.

Li C, Hu M, Cai S, Yang G, Yang L, Jing H Cancer Sci. 2024; 115(8):2528-2539.

PMID: 38720474 PMC: 11309950. DOI: 10.1111/cas.16206.

Low expression of lysosome-related genes KCNE1, NPC2, and SFTPD promote cancer cell proliferation and tumor associated M2 macrophage polarization in lung adenocarcinoma.

Wang Z, Ning Z, Ma C, Liu T, Tao B, Guo L Heliyon. 2024; 10(6):e27575.

PMID: 38509982 PMC: 10950582. DOI: 10.1016/j.heliyon.2024.e27575.

References

Gupta N, Tamim W, Graeber G, Bishop H, Hobbs G . Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest. 2001; 120(2):521-7. DOI: 10.1378/chest.120.2.521. View

Toloza E, Harpole L, McCrory D . Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003; 123(1 Suppl):137S-146S. DOI: 10.1378/chest.123.1_suppl.137s. View

Birim O, Kappetein A, Stijnen T, Bogers A . Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2004; 79(1):375-82. DOI: 10.1016/j.athoracsur.2004.06.041. View

Meyers B, Haddad F, Siegel B, Zoole J, Battafarano R, Veeramachaneni N . Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2006; 131(4):822-9. DOI: 10.1016/j.jtcvs.2005.10.045. View

Inoue M, Minami M, Shiono H, Sawabata N, Ideguchi K, Okumura M . Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement. J Thorac Cardiovasc Surg. 2006; 131(5):988-93. DOI: 10.1016/j.jtcvs.2005.12.035. View

Koike T, Tsuchiya R, Goya T, Sohara Y, Miyaoka E . Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. J Thorac Oncol. 2007; 2(5):408-13. DOI: 10.1097/01.JTO.0000268674.02744.f9. View

Uy K, Darling G, Xu W, Yi Q, de Perrot M, Pierre A . Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007; 134(1):188-93. DOI: 10.1016/j.jtcvs.2007.01.078. View

Silvestri G, Gould M, Margolis M, Tanoue L, McCrory D, Toloza E . Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):178S-201S. DOI: 10.1378/chest.07-1360. View

Ricardi U, Filippi A, Guarneri A, Romana Giglioli F, Ciammella P, Franco P . Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer. 2009; 68(1):72-7. DOI: 10.1016/j.lungcan.2009.05.007. View

10.

Grills I, Mangona V, Welsh R, Chmielewski G, McInerney E, Martin S . Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010; 28(6):928-35. DOI: 10.1200/JCO.2009.25.0928. View

11.

Burdick M, Stephans K, Reddy C, Djemil T, Srinivas S, Videtic G . Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 78(4):1033-9. DOI: 10.1016/j.ijrobp.2009.09.081. View

12.

Travis W, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y . International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6(2):244-85. PMC: 4513953. DOI: 10.1097/JTO.0b013e318206a221. View

13.

Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M . Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study. J Thorac Cardiovasc Surg. 2011; 143(3):607-12. DOI: 10.1016/j.jtcvs.2011.10.037. View

14.

Scagliotti G, Pastorino U, Vansteenkiste J, Spaggiari L, Facciolo F, Orlowski T . Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2011; 30(2):172-8. DOI: 10.1200/JCO.2010.33.7089. View

15.

Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M . Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. J Thorac Cardiovasc Surg. 2012; 144(6):1365-71. DOI: 10.1016/j.jtcvs.2012.07.012. View

16.

Maeyashiki T, Suzuki K, Hattori A, Matsunaga T, Takamochi K, Oh S . The size of consolidation on thin-section computed tomography is a better predictor of survival than the maximum tumour dimension in resectable lung cancer. Eur J Cardiothorac Surg. 2012; 43(5):915-8. DOI: 10.1093/ejcts/ezs516. View

17.

Li L, Ren S, Zhang Y, Guan Y, Zhao J, Liu J . Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic. Lung Cancer. 2013; 81(2):213-7. DOI: 10.1016/j.lungcan.2013.04.012. View

18.

Ye B, Cheng M, Li W, Ge X, Geng J, Feng J . Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2014; 98(1):217-23. DOI: 10.1016/j.athoracsur.2014.03.005. View

19.

Ezer N, Veluswamy R, Mhango G, Rosenzweig K, Powell C, Wisnivesky J . Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer. J Thorac Oncol. 2015; 10(8):1201-6. PMC: 4511922. DOI: 10.1097/JTO.0000000000000600. View

20.

Hung J, Yeh Y, Jeng W, Wu Y, Chou T, Hsu W . Factors predicting occult lymph node metastasis in completely resected lung adenocarcinoma of 3 cm or smaller. Eur J Cardiothorac Surg. 2016; 50(2):329-36. DOI: 10.1093/ejcts/ezv485. View